哮喘儿童吸入糖皮质激素与肺炎住院风险:全国性队列研究
采用倾向评分重叠加权调整混杂因素后,ICS使用与肺炎住院风险无显著关联(加权HR 1.06,95%CI 0.88-1.28)。
要点
- 在哮喘儿童中,ICS使用与肺炎住院风险无显著关联(加权HR 1.06,95%CI 0.88-1.28)。
- ICS使用组与未使用组的加权肺炎住院发生率相近(14.5 vs 14.6/万患者年)。
- 绝对率差为-0.06/万患者年(95%CI -2.83至2.72),未见临床有意义的差异。
核心结论
- 在哮喘儿童中,与未使用ICS相比,ICS使用未显示与肺炎住院风险存在关联。
研究设计与样本
- 从425 965例确诊哮喘的2-17岁儿童中,依据配药记录识别新使用ICS和未使用ICS的时段。
- 采用倾向评分重叠加权调整潜在混杂因素,主要结局为以肺炎为主要诊断的住院。
主要发现
- 共识别249 351个ICS使用时段(平均随访0.9年)和214 840个未使用时段(平均随访0.7年)。
- 随访期间,ICS使用时段观察到369例肺炎住院事件,未使用时段观察到181例。
- ICS使用与未使用的加权肺炎住院发生率分别为14.5和14.6每万患者年。
- 加权HR为1.06(95%CI 0.88至1.28),绝对率差为-0.06(95%CI -2.83至2.72)每万患者年。
临床怎么用
- 对于2-17岁哮喘儿童,不应因担忧肺炎住院风险而限制ICS的合理使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential association between the use of inhaled corticosteroids (ICS) and the risk of pneumonia among adults is disputed and paediatric-specific evidence is scarce. AIM: To assess the potential association between ICS, use and the risk of hospitalisation for pneumonia among children (age 2-17 years) with asthma. METHODS: This was a cohort study based on nationwide data from routine clinical practice in Sweden (January 2007 to November 2021). From 425 965 children with confirmed asthma, episodes of new ICS use and no use were identified using records of dispensed drugs. We adjusted for potential confounders with propensity score overlap weighting and the risk of a hospitalisation with pneumonia as primary diagnosis was estimated. Multiple subgroup and sensitivity analyses were also performed. RESULTS: We identified 249 351 ICS (mean follow-up of 0.9 years) and 214 840 no-use (mean follow-up of 0.7 years) episodes. During follow-up, 369 and 181 events of hospitalisation for pneumonia were observed in the ICS and no-use episodes, respectively. The weighted incidence rates of hospitalisation for pneumonia was 14.5 per 10 000 patient-years for ICS use episodes and 14.6 for no-use episodes. The weighted HR for hospitalisation for pneumonia associated with ICS use was 1.06 (95% CI 0.88 to 1.28) and the absolute rate difference was -0.06 (95% CI -2.83 to 2.72) events per 10 000 patient-years, compared with no use. CONCLUSIONS: In this nationwide cohort study, we found no evidence of an association between ICS use and the risk of hospitalisation for pneumonia among children with asthma, as compared with no use.
引用
- Sielinou Kamgang KH, Rhedin SA, Almqvist C, et al. Use of inhaled corticosteroids and the risk of hospitalisation for pneumonia in children with asthma: a nationwide cohort study. Thorax. 2024. PMID: 38184370. doi:10.1136/thorax-2023-220742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。